Ubamatamab (REGN4018, MUC16xCD3 bispecific antibody) monotherapy in patients with recurrent ovarian cancer (OC): Phase I dose-escalation analysis Meeting Abstract
| Authors: | Van Nieuwenhuysen, E.; O'Malley, D.; O'Cearbhaill, R. E.; Moore, K. N.; Hamilton, E. P.; Yeku, O.; Bouberhan, S.; Hou, J. Y.; Yoo, S. Y.; Brouwer-Visser, J.; Cheung, H. K.; Peterman, M.; Goncalves, P.; Schmidt, T.; Zhu, M.; Lowy, I.; Rowlands, T.; Uldrick, T. S.; Miller, E. A.; Liu, J. F. |
| Abstract Title: | Ubamatamab (REGN4018, MUC16xCD3 bispecific antibody) monotherapy in patients with recurrent ovarian cancer (OC): Phase I dose-escalation analysis |
| Meeting Title: | ESMO Congress 2022 |
| Journal Title: | Annals of Oncology |
| Volume: | 33 |
| Issue: | Suppl. 7 |
| Meeting Dates: | 2022 Sep 9-13 |
| Meeting Location: | Paris, France |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2022-09-01 |
| Start Page: | S784 |
| Language: | English |
| ACCESSION: | WOS:000866211600516 |
| DOI: | 10.1016/j.annonc.2022.07.651 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 523MO -- Source: Wos |
